# Nano Nuclear Energy Inc.: financial statements, quarterly

NNE · Nasdaq · CIK 1923891 · [Utilities](/sectors/utilities.md) · fiscal year ends Sep 30

Pages: [Overview](/companies/nne.md) · [Financials](/companies/nne/financials.md) · [Filings](/companies/nne/filings.md) · [Insiders](/companies/nne/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/nne/financials.md?period=annual).

## Income statement

| Line item | Unit | period not labelled (2023-09-30) | period not labelled (2023-12-31) | Q2 FY2024 (2024-03-31) | Q3 FY2024 (2024-06-30) | Q4 FY2024 (2024-09-30) | Q1 FY2025 (2024-12-31) | Q2 FY2025 (2025-03-31) | Q3 FY2025 (2025-06-30) | Q4 FY2025 (2025-09-30) | Q1 FY2026 (2025-12-31) | Q2 FY2026 (2026-03-31) | Q3 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | [0.2](/filings/0001493152-26-037345.md) |
| Cost of revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | [0.2](/filings/0001493152-26-037345.md) |
| Gross profit | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | [0.1](/filings/0001493152-26-037345.md) |
| Research and development | $m | [0.4 d](/filings/0001493152-24-052393.md) | [0.5](/filings/0001493152-25-006474.md) | [0.3](/filings/0001641172-25-010980.md) | [2.0](/filings/0001493152-25-011973.md) | [0.9 d](/filings/0001493152-25-028285.md) | [0.9](/filings/0001493152-26-007105.md) | [6.7](/filings/0001493152-26-023071.md) | [3.7](/filings/0001493152-26-037345.md) | [4.2 d](/filings/0001493152-25-028285.md) | [5.4](/filings/0001493152-26-007105.md) | [5.7](/filings/0001493152-26-023071.md) | [4.0](/filings/0001493152-26-037345.md) |
| Operating income | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | [(9.4)](/filings/0001493152-26-037345.md) | not reported | not reported | not reported | [(15.8)](/filings/0001493152-26-037345.md) |
| Net income | $m | [(1.3) d](/filings/0001493152-24-052393.md) | [(1.3)](/filings/0001493152-25-006474.md) | [(1.7)](/filings/0001641172-25-010980.md) | [(4.7)](/filings/0001493152-25-011973.md) | [(2.5) d](/filings/0001493152-25-028285.md) | [(3.1)](/filings/0001493152-26-007105.md) | [(21.3)](/filings/0001493152-26-023071.md) | [(7.6)](/filings/0001493152-26-037345.md) | [(8.1) d](/filings/0001493152-26-037345.md) | [(6.5)](/filings/0001493152-26-007105.md) | [(9.2)](/filings/0001493152-26-023071.md) | [(10.1)](/filings/0001493152-26-037345.md) |
| Diluted EPS | $ per share | not reported | [(0.06)](/filings/0001493152-25-006474.md) | [(0.07)](/filings/0001641172-25-010980.md) | [(0.17)](/filings/0001493152-25-011973.md) | not reported | [(0.09)](/filings/0001493152-26-007105.md) | [(0.57)](/filings/0001493152-26-023071.md) | [(0.19)](/filings/0001493152-26-037345.md) | not reported | [(0.13)](/filings/0001493152-26-007105.md) | [(0.18)](/filings/0001493152-26-023071.md) | [(0.19)](/filings/0001493152-26-037345.md) |
| Basic EPS | $ per share | not reported | [(0.06)](/filings/0001493152-25-006474.md) | [(0.07)](/filings/0001641172-25-010980.md) | [(0.17)](/filings/0001493152-25-011973.md) | not reported | [(0.09)](/filings/0001493152-26-007105.md) | [(0.57)](/filings/0001493152-26-023071.md) | [(0.19)](/filings/0001493152-26-037345.md) | not reported | [(0.13)](/filings/0001493152-26-007105.md) | [(0.18)](/filings/0001493152-26-023071.md) | [(0.19)](/filings/0001493152-26-037345.md) |

- Revenue: us-gaap:Revenues
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | period not labelled (2023-09-30) | period not labelled (2023-12-31) | Q2 FY2024 (2024-03-31) | Q3 FY2024 (2024-06-30) | FY2024 (2024-09-30) | Q1 FY2025 (2024-12-31) | Q2 FY2025 (2025-03-31) | Q3 FY2025 (2025-06-30) | FY2025 (2025-09-30) | Q1 FY2026 (2025-12-31) | Q2 FY2026 (2026-03-31) | Q3 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [7.0](/filings/0001493152-24-024530.md) | not reported | [6.0](/filings/0001493152-24-024530.md) | not reported | [28.5](/filings/0001493152-25-028285.md) | [123](/filings/0001493152-25-006474.md) | [119](/filings/0001641172-25-010980.md) | [210](/filings/0001493152-25-011973.md) | [203](/filings/0001493152-26-037345.md) | [578](/filings/0001493152-26-007105.md) | [198](/filings/0001493152-26-023071.md) | [298](/filings/0001493152-26-037345.md) |
| Current assets | $m | [7.2](/filings/0001493152-24-052393.md) | not reported | [6.6](/filings/0001493152-24-024530.md) | [14.3](/filings/0001493152-24-032196.md) | [29.3](/filings/0001493152-25-028285.md) | [128](/filings/0001493152-25-006474.md) | [119](/filings/0001641172-25-010980.md) | [212](/filings/0001493152-25-011973.md) | [205](/filings/0001493152-26-037345.md) | [581](/filings/0001493152-26-007105.md) | [572](/filings/0001493152-26-023071.md) | [585](/filings/0001493152-26-037345.md) |
| Total assets | $m | [7.2](/filings/0001493152-24-052393.md) | not reported | [8.9](/filings/0001493152-24-024530.md) | [16.4](/filings/0001493152-24-032196.md) | [35.1](/filings/0001493152-25-028285.md) | [134](/filings/0001493152-25-006474.md) | [139](/filings/0001641172-25-010980.md) | [232](/filings/0001493152-25-011973.md) | [229](/filings/0001493152-26-037345.md) | [606](/filings/0001493152-26-007105.md) | [604](/filings/0001493152-26-023071.md) | [628](/filings/0001493152-26-037345.md) |
| Current liabilities | $m | [0.2](/filings/0001493152-24-052393.md) | not reported | [0.6](/filings/0001493152-24-024530.md) | [1.8](/filings/0001493152-24-032196.md) | [1.8](/filings/0001493152-25-028285.md) | [2.5](/filings/0001493152-25-006474.md) | [4.4](/filings/0001641172-25-010980.md) | [2.9](/filings/0001493152-25-011973.md) | [3.8](/filings/0001493152-26-037345.md) | [4.3](/filings/0001493152-26-007105.md) | [6.0](/filings/0001493152-26-023071.md) | [7.4](/filings/0001493152-26-037345.md) |
| Total liabilities | $m | [0.2](/filings/0001493152-24-052393.md) | not reported | [2.2](/filings/0001493152-24-024530.md) | [3.4](/filings/0001493152-24-032196.md) | [3.5](/filings/0001493152-25-028285.md) | [4.1](/filings/0001493152-25-006474.md) | [6.8](/filings/0001641172-25-010980.md) | [5.2](/filings/0001493152-25-011973.md) | [6.1](/filings/0001493152-26-037345.md) | [6.5](/filings/0001493152-26-007105.md) | [8.0](/filings/0001493152-26-023071.md) | [12.0](/filings/0001493152-26-037345.md) |
| Shareholders' equity | $m | [2.0](/filings/0001493152-25-028285.md) | [2.8](/filings/0001641172-25-010980.md) | [6.6](/filings/0001493152-25-011973.md) | [13.0](/filings/0001493152-25-011973.md) | [31.6](/filings/0001493152-26-037345.md) | [130](/filings/0001493152-26-023071.md) | [132](/filings/0001493152-26-037345.md) | [226](/filings/0001493152-26-037345.md) | [223](/filings/0001493152-26-037345.md) | [600](/filings/0001493152-26-023071.md) | [596](/filings/0001493152-26-037345.md) | [616](/filings/0001493152-26-037345.md) |

- Cash and equivalents: us-gaap:Cash, us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | period not labelled (2023-09-30) | period not labelled (2023-12-31) | Q2 FY2024 (2024-03-31) | Q3 FY2024 (2024-06-30) | Q4 FY2024 (2024-09-30) | Q1 FY2025 (2024-12-31) | Q2 FY2025 (2025-03-31) | Q3 FY2025 (2025-06-30) | Q4 FY2025 (2025-09-30) | Q1 FY2026 (2025-12-31) | Q2 FY2026 (2026-03-31) | Q3 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(1,176) d](/filings/0001493152-24-052393.md) | [(1,107)](/filings/0001493152-25-006474.md) | [(2,302) d](/filings/0001641172-25-010980.md) | [(2,545) d](/filings/0001493152-25-011973.md) | [(2,510) d](/filings/0001493152-25-028285.md) | [(3,243)](/filings/0001493152-26-007105.md) | [(2,378) d](/filings/0001493152-26-023071.md) | [(9,093) d](/filings/0001493152-26-037345.md) | [(4,908) d](/filings/0001493152-26-037345.md) | [(3,990)](/filings/0001493152-26-007105.md) | [(5,264) d](/filings/0001493152-26-023071.md) | [(9,410) d](/filings/0001493152-26-037345.md) |
| Capital expenditure | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | [176 d](/filings/0001493152-26-037345.md) | [4,648 d](/filings/0001493152-25-028285.md) | not reported | not reported | [1,067 d](/filings/0001493152-26-037345.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | period not labelled (2023-03-31) | period not labelled (2023-06-30) | period not labelled (2023-12-31) | Q2 FY2024 (2024-03-31) | Q3 FY2024 (2024-06-30) | Q1 FY2025 (2024-12-31) | Q2 FY2025 (2025-03-31) | Q3 FY2025 (2025-06-30) | Q1 FY2026 (2025-12-31) | Q2 FY2026 (2026-03-31) | Q3 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [22.3](/filings/0001493152-24-024530.md) | [22.8](/filings/0001493152-24-032196.md) | [23.2](/filings/0001493152-25-006474.md) | [23.9](/filings/0001641172-25-010980.md) | [27.7](/filings/0001493152-25-011973.md) | [34.0](/filings/0001493152-26-007105.md) | [37.1](/filings/0001493152-26-023071.md) | [39.0](/filings/0001493152-26-037345.md) | [49.8](/filings/0001493152-26-007105.md) | [51.6](/filings/0001493152-26-023071.md) | [52.3](/filings/0001493152-26-037345.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 53,698,146 at 2026-08-10, from the cover of the [10-Q filed 2026-08-12](/filings/0001493152-26-037345.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:50 ET. No prices; not investment advice.